Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes
Michela Boi(Cornell University), Giorgio Inghirami(New York University)
Cited by 24
Related Papers
NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors
|Blood|2003|247
Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and Bcl2A1 as critical target genes
|Journal of Clinical Investigation|2006|164